Novavax, Inc.

NASDAQ:NVAX  
20.99
-1.45 (-6.46%)
Business Deals, Strategic Combinations, Products

Mabion Expands And Extends Deal With Novavax Till End-2026

Published: 09/23/2022 06:14 GMT
Novavax, Inc. (NVAX) - Said on Thursday It Has Signed Annex to Deal With Novavax for Contracted Commercial Production As Well As Annex to Commercial Scale Production Deal of Antigen to Covid-19 Vaccine Under Name of Nvx-cov2373 .
Under Annex, Novavax Has Also Committed to Take Actions Aiming at Immediately Ordering Company to Use Manufacturing Slot to Produce an Agreed by Parties Series of Antigen for Omicron Variant of Covid-19 Vaccine, Including Transfer of Technology.
Under Annex, Based on Schedule Set by Parties, Company Will Receive Remuneration for Production of Series of Product Or Remuneration for Capability to Manufacture Product Based on Production Force Guaranteed to Novavax .
Duration of Deal Has Been Extended Till End of 2026.